Driven by advances in molecular probe design and biomarker detection
methodologies, new imaging agents that can improve visualization of
pathologies and cellular processes are changing the practice of diagnostic
medicine. The ability of this new generation of contrast agents to detect
metabolic changes at the molecular level has significant potential for
improving visualization and quality of care. Targetable and activatable
imaging agents are gaining interest for a wide range of diagnostic
applications that include cardiology, neurology and soft tissue tumor
detection. The number of healthcare conditions that can be effectively imaged
noninvasively is expanding as a result of these innovative detection
technologies. Targeted and activatable imaging agents offer a unique
capability to generate unambiguous images by exploiting specific molecular
targets, pathways or cellular processes. This new wave of imaging agents
signals a paradigm shift in which the reagents take on new importance.
Highlights
Analyzes and assesses emerging imaging diagnostic candidates, their
capabilities, benefits, limitations and potential
Profiles development-stage imaging agents and examines their clinical
status and commercial prospects
Analyzes key industry alliances and partnerships by imaging modality, and
examines the impact of next-generation imaging candidates on future imaging
markets
Profiles market participants, their development activity and business
strategies
Evaluates the impact of economic, technology, and regulatory factors on
the development and commercialization of emerging imaging agents
Table of Contents
Table of Contents
Executive Summary
Diagnostic Imaging Market Dynamics
The Imaging Agent Landscape
Key Application Development Factors
Molecular Imaging Agent Marketspace
Commercial MIAs
Development Stage MIAs
Market Drivers
Industry Alignment and Competitive Landscape
Diagnostic Imaging Product Segment Analysis
Imaging Agent Product Segments and Commercial Potential
Antibodies
Conjugated Radioisotopes
Lanthanide Chelates
Metabolic Biomarkers
Optical Probes
Nanoparticles
Targeted Imaging Agents
Activatable Imaging Agents
Leading Academic/Research Programs/Centers
MIAs and Imaging Modalities - The Current Picture
MRI
Optical Imaging
PET
SPECT
Ultrasound
Evolution in Imaging Agent Market Segments
Disease Detection
Image-Guided Drug Delivery
Physiological Process Mapping
Therapeutic Screening
Treatment Assessment
Differential Diagnosis
MIAs in Healthcare - Clinical Applications
Physiological Visualization
Angiogenesis
Apoptosis
Inflammation
Neurology
Disease Detection and Therapeutic Management
Autoimmunity
Cardiology
Neurology
Oncology
Market Factors
Guidance, Rules and Regulations
Managed Care and Reimbursement
Academic and Private Sector R&D Programs
Alliances & Partnerships
Company Profiles
Molecular Imaging Agents: Targets, Technology, Markets and Commercial Opportunities published by Greystone Research Associates in October 5, 2012. This report consists of 170 Pages and the price starts from US $ 3850.
The contents of this page may be different from the latest version. Please contact us for details.
